Intelligent Bio Solutions INC 8-K filings

Intelligent Bio Solutions has successfully completed in-clinic testing for its fingerprint-based drug screening system, a key step towards FDA 510(k) submission.

Intelligent Bio Solutions Inc. reported a 148% increase in full-year revenue, reaching $3.11 million, and a 64% increase in fourth-quarter revenue, totaling $0.73 million.

Intelligent Bio Solutions Inc. has entered into an agreement to sell up to $3 million of its common stock through an at-the-market offering.

Intelligent Bio Solutions Inc. reports a substantial 148% year-over-year revenue increase for fiscal year 2024, driven by strong demand for its non-invasive drug testing solutions.

Intelligent Bio Solutions Inc. announced significant progress in its clinical study plan, moving closer to its FDA 510(k) submission for its fingerprint drug screening system.

Intelligent Bio Solutions Inc. reports a significant 118% year-over-year increase in its customer employee base, reaching an estimated total of 1.4 million employees.

Intelligent Bio Solutions Inc. announced it has surpassed 1,000 installed drug screening readers, marking a significant milestone and demonstrating strong year-over-year growth in both reader and cartridge sales.

Intelligent Bio Solutions Inc. emphasizes the increasing need for drug testing solutions across critical sectors due to rising on-the-job drug use.

Intelligent Bio Solutions has partnered with CenExel to conduct a method comparison clinical study, a key step in their FDA 510(k) submission process for their fingerprint drug screening system.

Intelligent Bio Solutions Inc. has partnered with QabasTech to exclusively distribute its drug screening technology in Saudi Arabia.

Intelligent Bio Solutions Inc. has increased the annual base salaries of its CEO and CFO, effective April 1, 2024.

Intelligent Bio Solutions Inc. reports the passing of board member Lawrence Fisher and subsequent adjustments to board size and committee compositions.

Intelligent Bio Solutions Inc. has successfully completed biocompatibility testing for its fingerprint drug screening system, a crucial step towards FDA 510(k) clearance.

Intelligent Bio Solutions has successfully completed the in-clinic portion of its pharmacokinetic study, a crucial step in its 510(k) regulatory approval pathway.

Intelligent Bio Solutions has begun dosing and sampling subjects in its Pharmacokinetic study, a crucial step towards FDA 510(k) submission for its fingerprint drug screening technology.

Intelligent Bio Solutions Inc. reports the resignation of a director and the appointment of a new director, along with changes to committee memberships.

Intelligent Bio Solutions has successfully recruited subjects and commenced screening for its pharmacokinetic study, a key step in its FDA 510(k) regulatory pathway.

Intelligent Bio Solutions reports a 193% year-over-year revenue increase, with 93% of that revenue coming from the UK, driven by its innovative drug testing solutions.

Intelligent Bio Solutions successfully exhibited its fingerprint drug screening technology at The Health & Safety Event 2024, a major UK industry showcase.

Intelligent Bio Solutions Inc. announced an 80% year-over-year revenue increase for the fiscal third quarter and a 193% increase for the nine months ended March 31, 2024, alongside progress in FDA 510(k) clinical studies.

Intelligent Bio Solutions Inc. reports a total of 3,117,049 outstanding common shares as of April 29, 2024, following recent stock issuances and warrant exercises.

Intelligent Bio Solutions Inc. announced a significant 80% year-over-year revenue increase for the fiscal third quarter and a 193% increase for the nine months ended March 31, 2024.

Intelligent Bio Solutions' subsidiary, Intelligent Fingerprinting, has been granted a European patent for its DSR-Plus Cartridge Reader, further protecting its innovative drug screening technology.

Intelligent Bio Solutions Inc. released a presentation on April 9, 2024, detailing the company's business and operations.

Intelligent Bio Solutions Inc. has successfully completed a $10.1 million private placement to institutional and accredited investors.

Intelligent Bio Solutions Inc. has entered into agreements with C2C Advisors Inc. and ClearThink Capital LLC for advisory and investor relations services, involving cash payments and stock grants.

Intelligent Bio Solutions has partnered with Cliantha Research to conduct a pharmacokinetic study as part of its FDA 510(k) clinical study plan for its fingerprint drug screening system.

Intelligent Bio Solutions Inc. has successfully regained compliance with Nasdaq listing requirements regarding minimum share price and stockholders' equity.

Intelligent Bio Solutions Inc. reported a 114% year-over-year revenue increase for the fiscal second quarter and a 337% increase for the six-month period ending December 31, 2023, driven by product sales and market expansion.

Intelligent Bio Solutions Inc. has generated approximately $1.77 million in gross proceeds by inducing the exercise of existing warrants and issuing new replacement warrants.